Distribution characteristics of mitoxantrone in a patient undergoing hemodialysis

• Published in: Cancer chemotherapy and pharmacology Vol. 31; no. 1; p. 57
• Main Authors: Boros, L, Cacek, T, Pine, R B, Battaglia, A C
• Format: Journal Article
• Language: English
• Published: Germany 01.01.1992
• Subjects: Aged; Female; Humans; Lymphoma - blood; Lymphoma - metabolism; Mitoxantrone - blood; Mitoxantrone - pharmacokinetics; Renal Dialysis; Renal Insufficiency - blood; Renal Insufficiency - metabolism; Renal Insufficiency - therapy; Time Factors; Tissue Distribution; Tumor Lysis Syndrome - blood; Tumor Lysis Syndrome - metabolism
• ISSN: 0344-5704
• DOI: 10.1007/BF00695995

The pharmacokinetic profile of mitoxantrone in a patient undergoing hemodialysis is described. Significant characteristics of our patient included lymphoma with liver involvement, tumor lysis syndrome, renal and hepatic failure. Combination chemotherapy consisted of mitoxantrone, vincristine, and cyclophosphamide. Mitoxantrone plasma samples were obtained prior to dosing and at 0, 0.25, 0.5, 0.75, 1.0, 1.5, 2.0, 2.5, 3.0, 3.5, 4.0, 4.5, 5.5, 7.0, and 12 h after the intravenous infusion of a 17-mg dose over 20 min. Serum concentrations were determined by high-performance liquid chromatography. The serum concentration versus time curve was consistent with a three-compartment model. However, rebounds in serum drug concentrations were detected during the last portion of dialysis and after its completion. The gamma elimination half-life could not be determined due to the continued detection of rebounds in drug concentrations throughout the postdialysis sampling period. The alpha and beta distribution phases did not appear to be affected by hemodialysis. The peak mitoxantrone concentration fell within the reported range. Mitoxantrone does not appear to be eliminated by hemodialysis, and dose adjustments are not needed in patients undergoing this procedure.